Neurizon Therapeutics Limited
ABN 35 094 006 023
www.neurizon.com

9 November 2026

Section 708A Cleansing Statement

This notice is given by Neurizon Therapeutics Limited ACN 094 006 023 (**ASX: NUZ**) (**Company**) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**).

The Company hereby confirms that:

(a) it has today issued a total of 63,715,762 fully paid ordinary shares (**Shares**) as follows:
   (i) 61,764,704 Shares issued at an issue price of $0.068 per Share, in relation to the Placement to sophisticated and professional investors as announced on 2 November 2026;
   (ii) 1,489,520 Shares issued upon exercise of vested performance rights in accordance with the terms of the Neurizon Equity Incentive Plan; and
   (iii) 461,538 Shares issued at a deemed issue price of $0.065 per Share to an investor relations advisor as part consideration for services provided;

(b) the Shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;

(c) the Company is providing this notice under paragraph (5)(e) of section 708A of the Corporations Act;

(d) as at the date of this notice the Company, as a disclosing entity under the Corporations Act, has complied with:

   (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and

   (ii) sections 674 and 674A of the Corporations Act; and

(e) as at the date of this notice, there is no "excluded information" of the type referred to in sections 708A(7) and 708A(8) of the Corporations Act.

-ENDS-

This announcement has been authorised for release by the Board of Neurizon Therapeutics Limited.

For further information, please contact:

Marketing & Corporate Affairs
Lidija Damjanovic
Email: lidija@neurizon.com
Phone: +61 (0) 425 700 504

Investor Relations
Henry Jordan
Email: henry.jordan@sdir.com.au
Phone: +61 (0) 431 271 538

About Neurizon Therapeutics Limited

Neurizon Therapeutics Limited (ASX: NUZ) is a late clinical-stage biotechnology company dedicated to advancing treatments for neurodegenerative diseases. Neurizon is developing its lead drug candidate, NUZ-001, for the treatment of ALS, which is the most common form of motor neurone disease. Neurizon's strategy is to accelerate access to effective ALS treatments for patients while exploring the potential of NUZ-001 for broader neurodegenerative applications. Through international collaborations and rigorous clinical program, Neurizon is dedicated to creating new horizons for patients and families impacted by complex neural disorders. NUZ-001 is an investigational product and is not approved for commercial use in any jurisdiction.

Neurizon Investor Hub

We encourage you to utilise our Investor Hub for any enquiries regarding this announcement or other aspects concerning Neurizon.
This platform offers an opportunity to submit questions, share comments, and view video summaries of key announcements.

To access Neurizon Investor Hub please scan the QR code or visit https://investorhub.neurizon.com

Neurizon® is a registered trademark of Neurizon Therapeutics Limited